Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal (groups A, C, Y, W) conjugate vaccine
- Development stage
- Phase 3
- Lead developer
- Parent
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MenACYW quadrivalent meningococcal conjugate vaccine, marketed under the brand name MenQuadfi, is a vaccine developed by Sanofi Pasteur for active immunization against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. The vaccine is formulated by individually conjugating the capsular polysaccharides of these four serogroups to a tetanus toxoid carrier protein, which enhances immunogenicity by recruiting T-cell help. Approved by the FDA in 2020 and the EMA in 2020, MenQuadfi is administered as a single intramuscular injection and is indicated for individuals aged 6 weeks and older in the US and 12 months and older in Europe.
- Brand names
- MenQuadfi
- Other names
- MenACYW quadrivalent meningococcal conjugate vaccineMenACYW-TTMenACWY-TTmeningococcal (groups A, C, Y, W) polysaccharide tetanus toxoid conjugate vaccinemeningococcal group A, C, W-135 and Y conjugate vaccine
02
Targets
BCR (Immunoglobulin G B Cell Receptor)NeuraminidaseNmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)γδ TCR (T-cell receptor)TT (Tetanus toxoid)
Beyond the preview
Go deeper on meningococcal (groups A, C, Y, W) conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal (groups A, C, Y, W) conjugate vaccine.